C-Ray Therapeutics Group strategically operates through two entities:

C-Ray Therapeutics (Shanghai) serves as the R&D innovation engine, driving internal pipeline discovery and enhancing core platforms like targeted ligand discovery and high-throughput screening for novel RDC drugs.

C-Ray Therapeutics (Chengdu), the world-class CRDMO and manufacturing backbone.

The Chengdu base features ~30,000 m² of R&D/cGMP space, a Class A Radiation Safety License for 30+ isotopes, and 13 automated production lines. This supports the entire radiopharmaceutical chain, from novel ligand labeling (e.g., with Lu-177, Ac-225) to commercial supply.

Bolstered by over $187M in total funding, C-Ray Chengdu has proven its platform by executing 60+ CRDMO projects, with 2 already reaching Phase III trials. This integrated "R&D + CRDMO" model positions C-Ray as a powerful force in global radiopharmaceuticals.